Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10561 in Healthy Adults and Chronic Spontaneous Urticaria
NCT06864507Phase 2Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HS-10561 in chronic spontaneous urticaria (CSU) (4 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Adverse Events at 35 days and Weekly Urticaria Activity Score at Week 4. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
HS-10561
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06864507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06864507.